NRIX
Nurix Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -7.1% ·
share flow +3.1% ·
net new positions -7.7%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 80 | +2 | 57.55M | $1.40B | +9 | −7 |
| Q1 2026 | 81 | +9 | 58.06M | $899.96M | +14 | −5 |
| Q4 2025 | 72 | -4 | 55.79M | $1.06B | n/a | −4 |
| Q3 2025 | 18 | +1 | 36.35M | $335.90M | +1 | n/a |
| Q2 2025 | 14 | -2 | 38.82M | $442.11M | n/a | −2 |
| Q1 2025 | 13 | 0 | 15.31M | $181.88M | +1 | −1 |
| Q4 2024 | 13 | -1 | 15.53M | $292.61M | +1 | −2 |
| Q3 2024 | 13 | -1 | 13.04M | $292.98M | +1 | −2 |
| Q2 2024 | 14 | n/a | 12.64M | $263.85M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 3.48M | +8.8% | $78.24M | 0.0% | ▲ Add | 2 | SEC ↗ ×6 |
| 2 | T. Rowe Price ✦ | 3.07M | +8.2% | $68.96M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 3 | ARK Investment Management ✦ | 2.22M | -4.6% | $49.80M | 0.5% | ▼ Trim | 2 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 1.53M | +47.1% | $34.41M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 5 | Geode Capital Management ✦ (passive) | 1.45M | +9.6% | $32.54M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 6 | Norges Bank ✦ (passive) | 318.80K | -37.2% | $7.16M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | PRIMECAP Management ✦ | 290.00K | 0.0% | $6.52M | 0.0% | Held | 2 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 246.40K | -23.9% | $5.54M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 9 | Millennium Management ✦ | 221.72K | -63.0% | $4.98M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | D. E. Shaw & Co. ✦ | 72.84K | New | $1.64M | 0.0% | New | 1 | SEC ↗ |
| 11 | Two Sigma Investments ✦ | 50.71K | -16.7% | $1.14M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 46.92K | +120.3% | $1.05M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 13 | Duquesne Family Office ✦ | 44.20K | 0.0% | $993,000 | 0.0% | Held | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| D. E. Shaw & Co. | $1.64M | 0.0% |
Exited
| Arrowstreet Capital | $1.25M | was 0.0% |
| Gotham Asset Management | $247,769 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 194 holders, 116.98M shares, $1.75B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 1.45K sh · $36,300
Director · 22.58K sh · $528,528
Officer · 1.45K sh · $36,982
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology